Children’s Minnesota is pleased to announce that our cystic fibrosis (CF) program has been selected for the Cystic Fibrosis Foundation’s Quality Improvement Award.
The recognition celebrates programs that actively use clinical data to identify opportunities for improvement, consistently involve patients and families in designing these improvements, and employ innovative strategies to improve care. Our cystic fibrosis program was selected for its dedicated multidisciplinary care team, comprehensive trainee education, exceptional patient and family involvement, and communication tools that overcome barriers to care.
CF is a genetic condition that causes cells to produce mucus that is thicker and stickier, resulting in blocked ducts, which affects many systems in the body – from lungs and sinuses to sweat glands and the digestive system.
The cystic fibrosis program at Children’s Minnesota is led by Dr. Brooke Moore, chief of staff and pediatric pulmonologist, and includes a range of professionals, such as physicians, nurses, dietitians, respiratory therapists, physical therapists, genetic counselors, social workers and research coordinators. The program cares for approximately 150 kids per year.
“Congratulations to the cystic fibrosis program on this well-deserved recognition. Their dedication to finding new treatments and bringing these innovations to the bedside to improve kids’ quality of life is remarkable,” said Dr. Emily Chapman, chief medical officer and senior vice president of medical affairs at Children’s Minnesota. “From diagnosing and testing to treating and managing the challenges of living with CF, they deliver on our vision of being every family’s essential partner in raising healthier children.”
The CF program is accredited by the Cystic Fibrosis Foundation, meaning it offers the best care, treatment and support for children with the condition. Children’s Minnesota is also a designated Therapeutics Development Network center. This connects us with top cystic fibrosis centers around the world that are actively researching new treatments and gives our patients access to a wide range of clinical trials.
